Key result
Camrelizumab, apatinib, and radiotherapy achieve ~46% partial remission in one advanced alveolar soft part sarcoma patient.
Why the study?
The clinical relevance of immune checkpoint inhibitors alone or combined with other therapies in patients with alveolar soft part sarcoma remains unclear.
Does camrelizumab combined with apatinib improve treatment response in advanced alveolar soft part sarcoma?
Case Report (n=1)
Does camrelizumab combined with apatinib improve treatment response in advanced alveolar soft part sarcoma?
Camrelizumab combined with apatinib may be an effective and safe treatment regimen for patients with advanced alveolar soft part sarcoma resistant to conventional therapies.
May indicate activity in refractory disease; leaves open confirmation of benefit in prospective trials.
Alveolar soft part sarcoma (ASPS) is a rare and highly malignant mesenchymal tumor that primarily affects adolescents and young adults. ASPS is characterized by a slow growth rate, high metastatic potential, and resistance to conventional therapies. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignancies, improving the objective response rate (ORR) and prolonging patient survival. The combination of immunotherapy with targeted therapies can overcome resistance to treatment with ICIs alone. Although substantial progress has been made in various solid tumors, the clinical relevance of ICIs, used alone or in combination with other therapies, in patients with ASPS remains unclear. This is a case report of a 32-year-old man who was diagnosed with advanced ASPS. After 8 months of anlotinib treatment, the patient's disease progressed and new cerebellar metastases were detected. Radiotherapy was administered in addition to camrelizumab combined with apatinib to treat the brain metastases. The patient achieved partial remission (46%) after 3 months of treatment and did not present any severe side effects. This is the first reported case of the successful treatment of advanced ASPS with camrelizumab combined with apatinib. This case supports the use of a novel treatment regimen for patients with inoperable ASPS or ASPS that is resistant to conventional therapies.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) conducted a case report in Advanced alveolar soft part sarcoma (ASPS) (n=1). Camrelizumab combined with apatinib and radiotherapy was evaluated on Partial remission. Camrelizumab combined with apatinib and radiotherapy achieved a 46% partial remission after 3 months in a patient with advanced alveolar soft part sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: